Global registry for en bloc resection of bladder tumors
The Global En Bloc Resection of Bladder Tumour Registry
This study is trying to see if a new way to remove bladder tumors called en bloc resection works better than the usual method for helping adults with bladder cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Hong Kong and 1 other locations) |
| Trial ID | NCT04934540 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect data on the en bloc resection of bladder tumors (ERBT) globally over a five-year period to clarify its role in managing bladder cancer. Bladder cancer is a significant health burden, and the study focuses on comparing the effectiveness of ERBT against traditional methods like transurethral resection of bladder tumor (TURBT). By analyzing outcomes and recurrence rates, the study seeks to improve surgical techniques and patient management strategies for bladder cancer. The study includes adult patients with bladder tumors who consent to participate.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older with a diagnosed bladder tumor who are undergoing en bloc resection.
Not a fit: Patients with a history of upper tract urothelial carcinoma, other active malignancies, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance surgical techniques for bladder cancer, potentially leading to better patient outcomes and reduced recurrence rates.
How similar studies have performed: While the en bloc resection technique is relatively novel, previous studies have indicated that improved surgical methods can lead to better outcomes in bladder cancer management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients \>=18 years old with informed consent * Presence of bladder tumour undergoing transurethral ERBT Exclusion Criteria: * Presence or previous history of upper tract urothelial carcinoma * Presence of other active malignancy * Pregnancy
Where this trial is running
Hong Kong and 1 other locations
- North District Hospital — Hong Kong, Hong Kong (Recruiting)
- Prince of Wales Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Jeremy YC TEOH, FRCS(Ed) MBBS — Chinese University of Hong Kong
- Study coordinator: Jeremy YC TEOH, FRCS(Ed) MBBS
- Email: jeremyteoh@surgery.cuhk.edu.hk
- Phone: 852-35052625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.